Zoetis Inc. with ticker code (ZTS) now have 12 analysts in total covering the stock. The consensus rating is pointing to ‘Buy’. The range between the high target price and low target price is between 260 and 180 and has a mean target at $215.75. Now with the previous closing price of $166.31 this is indicating there is a potential upside of 29.7%. The day 50 moving average is $164.45 while the 200 day moving average is $160.19. The company has a market capitalization of $77,066m. Find out more information at: https://www.zoetis.com
The potential market cap would be $99,976m based on the market consensus.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms; vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides testing and analysis of blood, urine, and other animal samples and related products and services, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
The company has a dividend yield of 0.92% with the ex dividend date set at 20-4-2023 (DMY).
Other points of data to note are a P/E ratio of 36.39, revenue per share of 17.23 and a 12.73% return on assets.
